XML 143 R125.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTARY CONSOLIDATED FINANCIAL STATEMENT SCHEDULE VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)
$ in Millions
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Year $ 931 $ 160 $ 151
Charges (Credits) to Costs and Expenses (130) 819 45
Charged to Other Accounts (6) 14 9
Deductions From Allowance Accounts (275) (62) (45)
Balance at End of Year 520 931 160
Current allowances 500 921 158
Provision for bad debts (130) 819 45
U.S. Pharmaceutical      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Provision for bad debts (206) 725  
Allowances for credit losses      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Year 877 114 99
Charges (Credits) to Costs and Expenses (130) 819 45
Charged to Other Accounts (2) 5 5
Deductions From Allowance Accounts (273) (61) (35)
Balance at End of Year 472 877 114
Other allowances      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Balance at Beginning of Year 54 46 52
Charges (Credits) to Costs and Expenses 0 0 0
Charged to Other Accounts (4) 9 4
Deductions From Allowance Accounts (2) (1) (10)
Balance at End of Year 48 54 46
Written-off      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Deductions From Allowance Accounts (275) (62) (37)
Credited to other accounts and other      
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]      
Deductions From Allowance Accounts $ 0 $ 0 $ (8)